Literature DB >> 23390783

Value and validation of RCOST and TOPF clinical practice guideline for osteoporosis treatment.

Chatlert Pongchaiyakul1, Taninnit Leerapun, Sunton Wongsiri, Thawee Songpattanasilp, Nimit Taechakraichana.   

Abstract

OBJECTIVE: To determine the percentage of postmenopausal women who need treatment using the various criteria as set out in clinical practice guideline published by the Royal College of Orthopaedic Surgeons of Thailand (RCOST) and the Thai Osteoporosis Foundation (TOPF). MATERIAL AND
METHOD: A cross-sectional investigation conducted at five university hospitals around Thailand, evaluated three categories of criteria according to the RCOST and the TOPF guideline for treatment in postmenopausal women, (1) bone mineral density (BMID) measured by DXA, (2) combined quantitative ultrasonography (QUS) measurement and clinical risk indices (CRI), and (3) FRAX or CRI plus spine radiography.
RESULTS: One thousand sixty two woman averaging 60 years of age were recruited for this study. Of those, women with osteoporosis according to DXA, osteopenia plus FRAX, or one major or two minor risk factors comprised between 1 and 22% (category I). Using the QUS T-score in combination with CRI (OSTA or KKOS score < or = -1) or nomogram criteria, between 11 and 14.4% needed treatment (category II). Using the BMI-based FRAX calculation or CRI (OSTA score of < -4 or KKOS probability of > or =80%) plus osteopenia by spine radiograph, between 2.6 and 15.7% needed treatment (category III).
CONCLUSION: Using the RCOST and TOPF clinical practice guideline, only one-fifth of postmenopausal Thai women would be eligible to receive treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23390783

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

Review 1.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

2.  Temporal changes in access to FRAX® in Thailand between 2010 and 2018.

Authors:  Pojchong Chotiyarnwong; Nicholas C Harvey; Helena Johansson; Enwu Liu; Mattias Lorentzen; John A Kanis; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2019-06-21       Impact factor: 2.617

3.  A novel hybrid compound LLP2A-alendronate accelerates open fracture healing in a rabbit model.

Authors:  Zheng Wang; Yong Zhao; Dong Zhang; Baiwen Qi; Weidong Xiao; Xiang Hu; Aixi Yu
Journal:  Drug Des Devel Ther       Date:  2019-04-05       Impact factor: 4.162

4.  Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review.

Authors:  Michelle Gates; Jennifer Pillay; Guylène Thériault; Heather Limburg; Roland Grad; Scott Klarenbach; Christina Korownyk; Donna Reynolds; John J Riva; Brett D Thombs; Gregory A Kline; William D Leslie; Susan Courage; Ben Vandermeer; Robin Featherstone; Lisa Hartling
Journal:  Syst Rev       Date:  2019-08-23

5.  Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.

Authors:  Aasis Unnanuntana; Atthakorn Jarusriwanna; Panupan Songcharoen
Journal:  PLoS One       Date:  2017-07-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.